文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

2021-2022年美国马萨诸塞州SARS-CoV-2传播的基于人群的血清学调查

Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USA.
PubMed 文献 · Vaccine · 2025-11-18

2021年6月至2022年9月在马萨诸塞州开展五次序贯全州血清学调查,随机邀请52000户家庭,共2220名参与者完成问卷并提交有效标本,其中10人PCR阳性。五次调查中刺突抗体阳性率范围为83.1%至96.4%,刺突中和抗体点患病率从第1/2轮的20.5%升至第5轮的73.5%。多变量回归显示疫苗接种状态与SARS-CoV-2暴露血清标志物呈正相关,种族、年龄、收入和职业与血清状态无统计学显著关联。

要点

  • 五次重复横断面血清学调查显示刺突抗体阳性率范围为83.1%至96.4%。
  • 刺突中和抗体点患病率从第1/2轮的20.5%升至第5轮的73.5%。
  • 疫苗接种状态与所有SARS-CoV-2暴露血清标志物阳性呈正相关。

核心结论

  • 调查表明刺突蛋白抗体及中和抗体随时间增加,但中和抗体在不同社会人口学因素间无差异,提示调查期间全州在疫苗覆盖或感染相关抗体滴度方面不存在重大健康差异。
  • 应答率在部分人口学群体中较高(白人、高收入家庭和女性),因此过采样和加权得以估计更大的马萨诸塞州人群。
  • 作者认为中和抗体在不同人口学群体间无统计学显著差异,提示所有群体对SARS-CoV-2感染受到相似保护,结果突显马萨诸塞州在保护所有人口学个体方面的成功。

研究设计与样本

  • 2021年6月至2022年9月开展五次序贯全州血清学调查,对代表性不足的人口学群体进行过采样。
  • 采用基于邮件的重复横断面调查,覆盖疫苗快速接种和不同病毒变异株流行的时期。
  • 随机邀请52000户马萨诸塞州家庭参与,共2220名参与者完成人口学问卷并提交有效标本用于分析。
  • 收集居家鼻拭子用于PCR病毒学检测,收集干血斑卡用于ELISA检测SARS-CoV-2 IgG抗体血清标志物(包括刺突蛋白和核衣壳蛋白),并以血清阳性率报告。
  • 同时检测针对刺突受体结合域的中和抗体。

主要发现

  • 受邀的52000户家庭中,共2220名参与者完成人口学问卷并提交有效标本,其中10人在调查时SARS-CoV-2 PCR阳性。
  • 五次重复横断面调查中,刺突抗体阳性率范围为83.1%至96.4%。
  • 刺突中和抗体水平随每次调查增加,点患病率值从第1/2轮的20.5%升至第5轮的73.5%。
  • 使用加权数据,核衣壳蛋白血清阳性率在整个调查期间保持相对恒定,第3轮除外。
  • 多变量回归发现疫苗接种状态与SARS-CoV-2暴露血清标志物呈正相关,已接种疫苗个体更可能对所有血清标志物呈血清阳性;种族、年龄、收入和职业等因素与血清状态无统计学显著关联。

局限性

  • 应答率在部分人口学群体中较高(白人、高收入家庭和女性),因此采用过采样和加权以估计更大的马萨诸塞州人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SARS-CoV-2 has been responsible for extensive morbidity and mortality in Massachusetts, especially during the 2021-2022 time period. The true burden of infection is unknown as official reporting data during 2021 and 2022 was not able to capture subclinical/asymptomatic infections nor the results from home-based lateral flow tests (LFTs). AIM: This study was designed to better characterize the exposure of Massachusetts residents to SARS-CoV-2, and to understand demographic and behavioral factors associated with SARS-CoV-2 exposure during the highest burden years of the pandemic. METHODS: A series of five sequential state-wide serosurveys were conducted with oversampling for underrepresented demographic groups from June 2021 to September 2022. These mail-based, repeated cross-sectional surveys (RCSs) captured data at periods of rapid vaccine uptake when different viral variants were predominant. This study also included collection of at-home nasal swabs for PCR-based SARS-CoV-2 virological testing, and collection of dried blood spot cards for ELISA-based testing of SARS-CoV-2 IgG antibody seromarkers including spike and nucleocapsid protein, reported as seroprevelences. Neutralizing antibodies to spike-RBD were also measured. RESULTS: Of the randomly selected 52,000 Massachusetts households invited to participate in this survey, a total of 2220 participants completed the demographic questionnaire and submitted valid specimens for analysis. Of these participants, ten were PCR-positive for SARS-CoV-2 at time of survey. Across all five repeated cross-sectional surveys (RCS), spike antibody positivity ranged from 83.1 % to 96.4 %. Additionally, levels of the spike neutralizing antibody increased with each RCS; point prevalence values ranged from 20.5 % in RCS 1/2 to 73.5 % in RCS 5. Using weighted data, the seroprevalence of nucleocapsid protein remained relatively constant throughout the RCSs except for RCS 3. Multivariable regression results found a positive association between vaccination status and seromarkers of SARS-CoV-2 exposure; individuals who had been vaccinated were more likely to be seropositive for all seromarkers. Factors including race, age, income, and occupation did not show any statistically significant associations with serostatus. CONCLUSIONS: This survey indicates that while there was an increase in antibodies to spike protein and to associated neutralizing antibodies over time, there were no differences in neutralizing antibodies by socio-demographic factors, suggesting no major health disparities existed at the time of surveys in either vaccine coverage or infection-related antibody titers across the state. Response rates were higher among some demographic groups (Caucasians, households with a high income, and women), thus, oversampling and weighting allowed estimates of the larger Massachusetts population. Our findings that there were no statistically significant differences in neutralizing antibodies across demographic groups suggesting all groups were similarly protected from SARS-CoV-2 infection. These results highlight the success of Massachusetts in protecting individuals across all demographics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cramer EY, Dada AO, Onofrey S, et al. Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USA. Vaccine. 2025. PMID: 41260174. doi:10.1016/j.vaccine.2025.127952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。